9780323698283 - controversies in rheumatology: an issue of rheumatic disease clinics of north america: volume 45-3 (5 risultati)
- Rilegato
Da: Basi6 International, Irving, TX, U.S.A.Basi6 International
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 100,39
Spedizione gratuitaSpedito in U.S.A.Quantità: Più di 20 disponibili
Condizione: Brand New. New. Delivery takes 25-30 days. Excellent Customer Service.
- Rilegato
Da: Revaluation Books, Exeter, Regno UnitoRevaluation Books
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 113,89
EUR 11,67 spedizioneSpedito da Regno Unito a U.S.A.Quantità: 1 disponibili
Hardcover. Condizione: Brand New. 9.37x6.30x0.59 inches. In Stock.
- Rilegato
Da: THE SAINT BOOKSTORE, Southport, Regno UnitoTHE SAINT BOOKSTORE
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 124,51
EUR 17,34 spedizioneSpedito da Regno Unito a U.S.A.Quantità: 1 disponibili
Hardback. Condizione: New. New copy - Usually dispatched within 4 working days.
- Rilegato
- Print on Demand
Da: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, GermaniaBuchWeltWeit Ludwig Meier e.K.
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 108,99
EUR 23,00 spedizioneSpedito da Germania a U.S.A.Quantità: 2 disponibili
Buch. Condizione: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Guest edited by Drs. Jonathan Kay and Sergio Schwartzman, this issue of Rheumatic Disease Clinics will cover Controversies in Rheumatology. This issue is one of four selected each year by our series Consulting Editor, Dr. Michael Weisman…of Cedars-Sinai. Articles explore several questions, including, but not limited to: Is triple therapy or methotrexate plus a biologic the initial treatment of choice for RA patients; Is hypo or hyper-uricemia a risk requiring treatment for cardiac morbidity and mortality; Are there benefits and risks to biosimilars from a patient perspective; Should platelet-rich plasma be used to treat osteoarthritis; Is there a role for stem cell therapy to treat cartilage defects in osteoarthritis; Should any rheumatology patient, today, be treated with bone marrow ablation and stem cell transplantation; Is there effective prevention, prophylaxis, or treatment for CPPD arthritis; Is fibromyalgia a psychiatric disease or a pain syndrome; Should cyclophosphamide still be used to treat ANCA-associated vasculitis; Does methotrexate have a place in the treatment of psoriatic arthritis; Should hydroxychloroquine dosing be limited because of potential ocular toxicity; and Should generalized immunosuppression or targeted organ treatment be the best principle for overall management of SLE. Englisch.
- Rilegato
- Print on Demand
Da: AHA-BUCH GmbH, Einbeck, GermaniaAHA-BUCH GmbH
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 108,99
EUR 62,05 spedizioneSpedito da Germania a U.S.A.Quantità: 2 disponibili
Buch. Condizione: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Guest edited by Drs. Jonathan Kay and Sergio Schwartzman, this issue of Rheumatic Disease Clinics will cover Controversies in Rheumatology. This issue is one of four selected each year by our series Consulting Editor, Dr. Michael Weisman of Ce…dars-Sinai. Articles explore several questions, including, but not limited to: Is triple therapy or methotrexate plus a biologic the initial treatment of choice for RA patients; Is hypo or hyper-uricemia a risk requiring treatment for cardiac morbidity and mortality; Are there benefits and risks to biosimilars from a patient perspective; Should platelet-rich plasma be used to treat osteoarthritis; Is there a role for stem cell therapy to treat cartilage defects in osteoarthritis; Should any rheumatology patient, today, be treated with bone marrow ablation and stem cell transplantation; Is there effective prevention, prophylaxis, or treatment for CPPD arthritis; Is fibromyalgia a psychiatric disease or a pain syndrome; Should cyclophosphamide still be used to treat ANCA-associated vasculitis; Does methotrexate have a place in the treatment of psoriatic arthritis; Should hydroxychloroquine dosing be limited because of potential ocular toxicity; and Should generalized immunosuppression or targeted organ treatment be the best principle for overall management of SLE.
